FDA Oncology Office Director Will Be Selected In Next Few Weeks
This article was originally published in The Pink Sheet Daily
The selection of a director for the new Office of Oncology Drug Products will be finalized in the next few weeks, FDA said
You may also be interested in...
The move, which had been scheduled for April, has been pushed back because the building is not ready, FDA says. The CDER reorganization is also being delayed to coincide with the move.
The agency formally announces creation of an Office of Oncology Drug Products. The new director will oversee the consolidation of three areas within the Center for Drug Evaluation & Research currently responsible for cancer drug reviews.
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.